Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22951263 | 1.00 | S1PR4 (0.32) | S1PR4S1PR1S1PR3S1PR5SMPD1 | |
| SCHEMBL22023657 | 0.93 | FDPS (0.33) | S1PR4S1PR1S1PR3S1PR5SMPD1 | |
| SCHEMBL19425843 | 0.73 | CNR2 (0.36) | CNR1CNR2 | |
| SCHEMBL20031361 | 0.72 | TLR8 (0.31) | — | |
| SCHEMBL19425824 | 0.72 | NPC1 (0.37) | — | |
| SCHEMBL23634144 | 0.71 | CNR2 (0.32) | S1PR4S1PR1S1PR3S1PR5CNR1 | |
| SCHEMBL23634128 | 0.71 | — | — | |
| SCHEMBL25101257 | 0.71 | CYP19A1 (0.31) | — | |
| SCHEMBL18867100 | 0.71 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL22951386 | 0.70 | KMT2A (0.31) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | S1PR4 4657/4885S1PR1 4186/4885S1PR3 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.